Results 11 to 20 of about 7,902 (191)
Enteropathy Associated with Olmesartan
The recognition of an enteropathy caused by olmesartan is recent. It was first described in 2012 by the Mayo Clinic, which presented 22 clinical cases. Olmesartan is a highly prescribed drug and the differential diagnosis of a sprue-like enteropathy is very wide, so it is important to be aware of this pathology.
Bruno Moreira da Silva +6 more
doaj +5 more sources
Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study [PDF]
Background/Aims Olmesartan, a widely used angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. No cases of olmesartan-associated enteropathy have been reported in Northeast Asia.
Seng Chan You +5 more
doaj +5 more sources
Synthesis and Characterization of Process-Related Impurities of Antihypertensive Drug Olmesartan Medoxomil [PDF]
Olmesartan medoxomil (1) is the latest angiotensin receptor antagonist approved by the FDA for the treatment of hypertension. During the process development of olmesartan medoxomil, three process-related impurities were observed along with the final API.
G. Venkanna +5 more
doaj +2 more sources
Olmesartan-Induced Enteropathy [PDF]
Olmesartan-induced enteropathy mimics celiac disease clinically and pathologically. As in celiac disease, the pathologic findings are villous atrophy and increased intraepithelial lymphocytes. Clinical presentation of olmesartan-induced enteropathy includes diarrhea, weight loss, and nausea. In contrast to celiac disease, tissue transglutaminase is not
Abimbola, Adike +5 more
openaire +3 more sources
OBJECTIVES: Remote ischemic perconditioning is the newest technique used to lessen ischemia/reperfusion injury. However, its effect in hypertensive animals has not been investigated.
Xin Lu, Yan-Wen Bi, Ke-Biao Chen
doaj +2 more sources
Anti-proliferative effect of olmesartan on Tenon's capsule fibroblasts [PDF]
AIM: To evaluate the inhibitive effect of olmesartan to fibroblast proliferation and the anti-scarring effect in Tenon’s capsule, both in vitro and in vivo.
Xuan Wang +3 more
doaj +2 more sources
Background: Olmesartan is an angiotensin II receptor antagonist and is effective and well tolerated in the treatment of arterial hypertension. Probenecid is a well-established hypouricemic agent for the treatment of hyperuricemia and gout. Objective: The
Kun-Yan Li, PhD +6 more
doaj +3 more sources
Takeshi Takami1, Yoshihiko Saito21Department of Internal Medicine, Clinic Jingumae, Kashihara, Japan; 2First Department of Internal Medicine, Nara Medical University, Kashihara, JapanPurpose: The aim of this study was to compare the effects of olmesartan
Takami T, Saito
doaj +1 more source
Olmesartan medoxomil: current status of its use in monotherapy
Hans R BrunnerLausanne University, Lausanne and Medizinische Poliklik, Universitaetsspital, Basel, SwitzerlandAbstract: Olmesartan medoxomil is an angiotensin II receptor antagonist.
Hans R Brunner
doaj +2 more sources
Gastrointestinal Disorder Associated with Olmesartan Mimics Autoimmune Enteropathy.
Background and objectivesAnti-hypertensive treatment with the angiotensin II receptor antagonist olmesartan is a rare cause of severe Sprue-like enteropathy. To substantiate the hypothesis that olmesartan interferes with gut immune homeostasis, clinical,
Sophie Scialom +15 more
doaj +2 more sources

